Translate Bio Shares Gain After FDA Grants Rare Pediatric Disease Designation
March 27 2020 - 7:04AM
Dow Jones News
By Chris Wack
Translate Bio Inc. shares were up 12% to $11.50 after the
company said the U.S. Food and Drug Administration has granted rare
pediatric disease designation for MRT5005 for the treatment of
cystic fibrosis.
MRT5005 is designed to deliver mRNA encoding fully functional
cystic fibrosis transmembrane conductance regulator protein to
cells in the lung through nebulization.
The therapeutics company said it anticipates Covid-19-related
interruptions in enrollment, dosing and follow-up in the ongoing
phase 1/2 clinical trial in patients with cystic fibrosis. The
company will provide updated timing on the expected interim data
readout of the additional single-ascending dose group and the
multiple-ascending dose portion of the clinical trial at a later
date.
TranslateBio also said it was working with French pharmaceutical
company Sanofi SA to develop a new mRNA vaccine candidate against
Covid-19, the disease caused by the new coronavirus.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 27, 2020 07:49 ET (11:49 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (EU:SAN)
Historical Stock Chart
From May 2023 to May 2024